ITM AG, a leading radiopharmaceutical company, today announced the establishment of a Chinese subsidiary, ITM (Shanghai) Precision Medical Co., Ltd., in Shanghai, China. The new subsidiary will be
(0)
Financing led by Petrichor Healthcare Capital Management strengthens company s global position as a leader in precision oncology and the field of Targeted Radionuclide Therapy ITM AG announced today the successful close of a convertible loan financing totaling EUR 90 million (USD 109 million) led by Petrichor Healthcare Capital Management with participation of additional undisclosed investors. The proceeds will support the expansion of ITM s precision oncology pipeline as well as fund late-stage development and market access activities for lead candidate, n.c.a.
177Lu-Edotreotide, currently in a phase III trial in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Under the terms of the agreement, the loan will convert into shares of ITM in the event of certain future financial or other corporate development transactions. Further details of the financing were not disclosed.
(0)
First pivotal study to compare Peptide Receptor Radionuclide Therapy (PRRT) in patients with Grade 1 and 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with approved standard of care ITM AG today announced the presentation of a trial-in-progress poster highlighting its ongoing Phase III trial COMPETE with n.c.a.
177Lu-Edotreotide in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021. The poster will be presented in video format as part of the Phase III trials in progress
poster session by Mona M. Wahba, MD, Deputy Chief Medical Officer at ITM. It will be available following the e-poster website launch on April 10, 2021, at 8:30 am ET 2:30 pm CET and remain available for viewing through June 21, 2021.
(1) ITM AG today announced that the company will present a poster describing the clinical trial design for its ongoing phase III trial COMPETE for their lead candidate, no-carrier-added Lutetium-177-Edotreotide (n.c.a.
177Lu-Edotreotide), a Targeted Radionuclide Therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting on April 10-15, 2021 and May 17-21, 2021.
The e-poster website will be launched on Saturday, April 10, 2021 at 8.30am ET and will remain available for viewing until Monday, June 21, 2021. Please see below for details on the poster abstract.
Session Category: Phase III Clinical Trials in Progress
Title: COMPETE Phase III Trial Peptide Receptor Radionuclide Therapy (PRRT) with